Skip to Content
Merck

Design, Synthesis, and Biological Evaluation of MEK PROTACs.

Journal of medicinal chemistry (2019-12-06)
Stefan Vollmer, Danen Cunoosamy, Huafei Lv, Huanxi Feng, Xia Li, Ziyang Nan, Wenzhen Yang, Matthew W D Perry
ABSTRACT

PROteolysis TArgeting Chimeras (PROTACs) targeting the degradation of MEK have been designed based on allosteric MEK inhibitors. Inhibition of the phosphorylation of ERK1/2 was less effective with the PROTACs than a small-molecule inhibitor; the best PROTACs, however, were more effective in inhibiting proliferation of A375 cells than an inhibitor.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
(S,R,S)-AHPC-Me, 95%